Specifically, the compound MW150 was active in APP-transgenic and tau-transgenic mice [121,123], the compounds MW181 and SB2399063 in aged tauopathy mice [122], and neflamapimod/VX-745 in aged rats [120]. This evidence concerns the gene MAPT and tauopathy.